Kim JY, Park K, Im SA, Jung KH, et al. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. Breast Cancer Res Treat 2020 Aug 28. pii: 10.1007/s10549-020-05891.
PMID: 32860168